Introduction {#s1}
============

Atrial fibrillation (AF) is the most prevalent heart rhythm disorder in the world, with nearly 7 million Americans and 34 million individuals globally affected by it ([@B1]--[@B4]). It is associated with heart failure, stroke, dementia, and poor quality of life ([@B1]). Clinical risk prediction scores, including CHA~2~DS~2~VASC, perform modestly well in predicting outcomes of AF but explain little about the mechanisms behind disease onset and progression and only explain a small proportion of observed risk. As such, it is important to examine the molecular processes that drive AF, as it may afford new biomarkers and therapeutic avenues.

MicroRNA (miRNA) is a class of small non-coding RNA that are endogenously produced and have important regulatory function. miRNAs have been implicated in structural and electrical remodeling that are central to the development of AF ([@B5]--[@B9]). In addition to their regulatory role, they serve as biomarkers of disease states, as they exist in the plasma with remarkable stability ([@B10]). Examining the plasma miRome has provided unique insight into the molecular processes that underlie the pathogenesis of AF.

Epicardial adipose tissue (EAT) is a layer of metabolically active adipocytes that lie between the visceral pericardium and the myocardium without fascial boundaries. Due to its close proximity, this adipose depot has paracrine and vasocrine effects on the myocardium and plays a critical role in the development and maintenance of AF ([@B11]--[@B13]). Several groups, including ours, have shown correlation between EAT and onset as well as severity of AF. Our group has previously shown that an indexed measure of EAT surrounding the left atrium, called iLAEAT, is independently associated with the severity and recurrence of AF after catheter ablation ([@B14]).

Although much is known about the interaction of these biomarkers individually and their effects on the pathogenesis of AF, the relationship between EAT and plasma miRNAs has not been studied before. Thus, we hypothesized that increasing levels of EAT measured on computed cardiac tomography are associated with expression of circulating plasma miRNAs and tested this using data from a prospectively recruiting, contemporary cohort of AF patients.

Methods {#s2}
=======

Study Population
----------------

As part of the miRhythm study examining links between circulating miRNAs and AF, 584 participants were recruited at the University of Massachusetts Medical Center (UMMC) between April 2011 to July 2017 ([@B15]). Study protocol was approved by the University of Massachusetts Institutional Review Board (IRB \#14875). Written consent was obtained from all participants to analyze pre-ablation miRNA expression. Of these, 91 participants underwent cardiac CT scan for evaluation of pulmonary venous anatomy prior to catheter ablation. These participants were included in our analysis. Participant information, including demographic, clinical, and baselines laboratory data, were abstracted from the UMMC AF Treatment Registry and hospital medical records by trained staff.

EAT Measurements
----------------

EAT was measured using validated methods ([@B16]). CT scans were performed by technicians at UMMC with the Siemens Somatom Definition Flash 128 dual source CT scanner. Unenhanced CT scans were taken with a standardized FLASH protocol. Enhanced scans were performed by injecting contrast dye and scanning using sequential acquisition. Calculation of contrast timing was done by giving the patient a 15 mL contrast test bolus followed by a 50 mL saline injection at 5--6 mL/s. Acquisition times were held constant between 1 and 2 s. EAT was measured by scanning the heart in a four-chamber view, with the bottom of the heart in front view. Locations of EAT around the right and left ventricles and the left atrium were traced by identifying regions of CT scans within a threshold of−43 Hounsfield units (HU) for unenhanced CT scans and−15 HU for enhanced CT scans. The inter and intra-observer reproducibility for EAT measurement was (*r* = 0.89 and 0.95), respectively. EAT was indexed to body surface area and reported as iLAEAT.

Echocardiographic Measurements
------------------------------

Complete 2D echocardiograms were performed during hospitalization. Linear dimensions and 2D volumes were measured according to ASE guidelines ([@B17]). We quantified left atrial (LA) volume), left ventricular end-diastolic (LVIDd) and end-systolic (LVIDs) dimensions, posterior wall thickness (PWT), interventricular septum thickness at end--diastole (IVSTd), left ventricular (LV) mass and left atrial function index (LAFI). LV mass was calculated by LV mass = 0.8 (1.04 \[LVID + PWTd + SWTd\]^3^ -- \[LVID\]^3^) + 0.6 g ([@B18]). LAFI was calculated by the previously validated formula: LAFI = LA emptying fraction^\*^LVOT-VTI / LAESVI ([@B19]).

MiRNA Identification and Profiling
----------------------------------

Ten cc of venous blood was obtained for study purposes after routine femoral venous sheath placement for catheter ablation of AF. This blood was processed to isolate plasma and stored as previously described ([@B20]). Briefly, blood was collected into blood collection tubes with solution containing sodium citrate. Samples were then centrifuged at 2,500 g for 22 min at 4°C. Plasma was separated from the cells and frozen at 80°C within 90 min of draw.

For this study, we selected 86 plasma miRNAs based on our RNAseq experiments done on 20 participants with cardiovascular disease and 20 without cardiovascular disease from the Framingham Heart Study Offspring 2 cohort (8th visit). We selected top expressed miRNAs from these 40 individuals for study in our RT-qPCR experiments ([@B20]). For all experiment, RNA was extracted from 200 μL of plasma. All methods used for cDNA synthesis, pre-amplification, and qPCR were performed according to Qiagen miScript Microfluidics Handbook by using Qiagen miScript Assays by the High-Throughput Gene Expression & Biomarker Core Laboratory at the University of Massachusetts Medical School ([@B21]). RNAs were isolated, and RT reactions performed by miScript II RT kit (Cat. No: 218161, Qiagen, Fredrick, MD, USA). miScript Microfluidics PreAMP Kit (Cat. No: 331455, Qiagen, Fredrick, MD, USA) was used for preamplification reactions. qPCR reactions were run using on BioMark System. BioMark System can detect single miRNA copy at 26--27 Cq compare to conventional qPCR platforms 36--37 ([@B22]).

We normalized the volume of plasma did not employ further methods of normalization in our dataset such as global mean normalization. Global mean is not ideal with our modest sample size and there are no reliable "housekeeper" gene to normalize miRNAs in the plasma ([@B20]). We believe that our Ct values are representative of relative concentrations. Differentially expressed miRNAs were analyzed using miRDB, an online database that captures miRNA and gene target interactions ([@B23], [@B24]). Network and functional analyses were generated through the use of Qiagen\'s Ingenuity Pathway Analysis ([@B25]).

Statistical Analyses
--------------------

Participants were divided into tertiles based upon iLAEAT values, placing them into either low (iLAEAT 0.08--0.59, *n* = 30), intermediate (iLAEAT 0.6--1.079, *n* = 31), or high (iLAEAT 1.08--3.58, *n* = 30) groups. Tertiles were created to identify participants at the greatest clinical risk for AF burden and recurrence. We examined the relationship between demographic, clinical, and echocardiographic variables and tertiles of iLAEAT using either χ^2^-squared tests for categorical variables or ANOVAs for continuous variables. A *p*-value of 0.05 was used as the standard significance threshold for statistical tests.

Pre-ablation miRNA expression was compared to iLAEAT using a series of linear regression models. Covariates included in the models were identified based upon characteristics that were determined to be significantly different between iLAEAT tertiles and included age, hypertension, heart failure, and posterior wall thickness. Bonferroni correction was also applied to account for multiple tests.

Results {#s3}
=======

We present participant characteristics based upon iLAEAT tertiles in [Table 1](#T1){ref-type="table"}. Participants almost exclusively identified as Caucasian (97%), and the majority were male (65%). Participants in the highest tertile of iLAEAT tended to be older, more likely to have a history of hypertension (86.7%, *p* = 0.01) and heart failure (26.7%, *p* = 0.01) and higher CHA~2~DS~2~-VASc scores (*p* = 0.04), thicker posterior walls (*p* = 0.01), and longer PR durations than did participants in the lower two tertiles. Participants with persistent AF have higher iLAEAT ([Figure 1](#F1){ref-type="fig"}). As previously observed, participants who have higher iLAEAT have a higher likelihood of having persistent AF ([@B14]). Furthermore, there is a non-significant association in decreasing LAFI with increasing iLAEAT tertile ([Figure 1](#F1){ref-type="fig"}).

###### 

Characteristics of study patients divided into iLAEAT tertiles.

  **Variable**                                          **Low iLAEAT**   **Intermediate iLAEAT**   **High iLAEAT**   ***P*-value**
  ----------------------------------------------------- ---------------- ------------------------- ----------------- -----------------------------------------
  Age (years)                                           55.9 ± 10.2      59.8 ± 9.8                61.2 ± 7.9        0.08[^\*\*^](#TN8){ref-type="table-fn"}
  Male sex *n* (%)                                      15 (50.0)        22 (71.0)                 22 (73.3)         0.11
  Body mass index (kg/m^2^)                             30.7 ± 6.8       32 ± 5.9                  31.5 ± 5.2        0.72
  **MEDICAL HISTORY**                                                                                                
  CHA2DS2-VASc score                                    1.7 ± 1.3        2.2 ± 1.5                 2.6 ± 1.1         0.04[^\*^](#TN7){ref-type="table-fn"}
  Smoking *n* (% reporting current/ex-smoker)           7 (23.3)         11 (35.5)                 12 (40.0)         0.36
  Diabetes mellitus *n* (%)                             3 (10.0)         9 (29.0)                  6 (20.0)          0.18
  Hypertension *n* (%)                                  16 (53.3)        24 (77.4)                 26 (86.7)         0.01[^\*^](#TN7){ref-type="table-fn"}
  Heart failure *n* (%)                                 0 (0.0)          5 (16.1)                  8 (26.7)          0.01[^\*^](#TN7){ref-type="table-fn"}
  Stroke/TIA *n* (%)                                    3 (10.0)         0 (0)                     2 (6.7)           0.22
  **ELECTROCARDIOGRAPHIC CHARACTERISTICS**                                                                           
  PR duration (msec)[^a^](#TN1){ref-type="table-fn"}    165.5 ± 39.3     185.7 ± 28.3              172.7 ± 27.1      0.09[^\*\*^](#TN8){ref-type="table-fn"}
  QRS Duration (msec)[^b^](#TN2){ref-type="table-fn"}   91.3 ± 20.9      94.3 ± 21.6               91 ± 15.7         0.81
  QTc duration (msec)[^c^](#TN3){ref-type="table-fn"}   514 ± 140.9      481.4 ± 123.6             443.6 ± 68.8      0.1
  **ECHOCARDIOGRAPHIC CHARACTERISTICS**                                                                              
  LVEF (%)[^d^](#TN4){ref-type="table-fn"}              58.2 ± 2.5       60 ± 5.6                  54.4 ± 8.6        0.15
  LA volume (mL)                                        78.0 ± 27.5      86.9 ± 20.1               83.3 ± 18.4       0.39
  LVIDd (mm) mean (SD)                                  48.9 ± 6.0       50.5 ± 5.7                46.8 ± 5.8        0.19
  LVIDs (mm) mean (SD)                                  31.5 ± 6.3       33.3 ± 5.6                30.1 ± 6.2        0.19
  PWT (mm) mean (SD)                                    9.7 ± 1.6        10.3 ± 1.6                11.0 ± 1.7        0.01[^\*^](#TN7){ref-type="table-fn"}
  IVSTd (mm) mean (SD)                                  10.2 ± 2.3       10.5 ± 1.7                11.2 ± 1.9        0.2
  LV mass (g)                                           172.1 ± 47.2     200.1 ± 64.1              186.9 ± 52.3      0.17
  **LABORATORY CHARACTERISTICS**                                                                                     
  BNP mean (pg/mL)[^e^](#TN5){ref-type="table-fn"}      106.8 ± 120.4    112.2 ± 140.0             116.0 ± 130.7     0.97
  CRP mean (mg/mL)[^f^](#TN6){ref-type="table-fn"}      5.7 ± 9.7        4.4 ± 7.1                 3.9 ± 3.2         0.71

BNP, B-Natriuretic Peptide; CRP, C-Reactive Protein; LA, Left Atrium; IVSTd, Interventricular Septum Thickness end-Diastole; LA AP diameter, Left Atrium Anterior-Posterior diameter; LV, Left Ventricle; LVIDd, Left Ventricular Internal Dimension at end-Diastole; LVIDs, Left Ventricular Internal Dimension at end-Systole; PWT, Posterior Wall Thickness; TIA, Transient Ischemic Attack.

PR data were available for 79 of the participants (29 for low iLAEAT, 23 for intermediate iLAEAT, and 27 for high iLAEAT).

QRS data were available for 80 of the participants (29 for low iLAEAT, 24 for intermediate iLAEAT, and 27 for high iLAEAT).

QTc data were available for 73 of the participants (28 for low iLAEAT, 20 for intermediate iLAEAT, and 25 for high iLAEAT).

EF data were available for 28 of the participants (11 for low iLAEAT, 9 for intermediate iLAEAT, and 8 for high iLAEAT).

BNP data were available for 68 of the participants (27 for low iLAEAT, 21 for intermediate iLAEAT, and 20 for high iLAEAT).

CRP data were available for 69 participants (28 for low iLAEAT, 22 for intermediate iLAEAT, and 19 for high iLAEAT).

Denotes significance of p \< 0.05 between tertiles.

Denotes marginal significance of p \< 0.1 between tertiles.

![iLAEAT and left atrial function. **(A)** iLAEAT is higher in participants with persistent AF. **(B)** LAFI tended to be lower in patients with higher iLAEAT tertile. iLAEAT and LAFI data were available for 71 participants in our cohort (26 for low iLAEAT, 23 for intermediate iLAEAT, and 22 for high iLAEAT). Statistical analysis was performed using unpaired student *t*-test for AF subtypes (\**p* \< 0.05) and one-way ANOVA analysis for iLAEAT tertiles. Error bars represent SEM. Panel **(A)** is adapted from work by Sanghai et al. ([@B14]).](fcvm-06-00115-g0001){#F1}

Results from qPCR analysis of 86 miRNAs are included in [Supplemental Table 1](#SM1){ref-type="supplementary-material"}. Analysis of miRNA expression level as well as regression models run between iLAEAT and Cq are illustrated in [Table 2](#T2){ref-type="table"}. After statistical correction for multiple tests, two miRNAs (miR-155-5p and−302a-3p) remained significantly associated with higher tertile of iLAEAT. Although, we do not know the source, potential targets or the mechanisms by which they are transported in the plasma, we believe that plasma miRNAs are derived from cellular sources. Therefore, analysis of miRNA downstream targets and pathways may reveal information regarding the molecular pathways that are activated.

###### 

Associations between iLAEAT and miRNAs.

  **MiRNA ID**        **b-coefficient**   **95% confidence intervals**   **Cq**        ***p*-value**   
  ------------------- ------------------- ------------------------------ ------------- --------------- -------------
  miRNA-100-5p        −0.09256            −0.16559                       −0.019533     19.08           0.013684
  miRNA-122-5p        −0.07597            −0.12271                       −0.029219     15.84           0.001798
  miRNA-106b-5p       −0.06955            −0.13335                       −0.005748     16.17           0.03305
  **miRNA-155-5p**    **0.01584**         **0.00769**                    **0.02399**   **12.98**       **0.00024**
  miRNA-184           0.01587             0.00351                        0.028234      5.67            0.01282
  miRNA-192-3p        0.01578             0.00133                        0.030232      4.78            0.032953
  miRNA-199a-5p       0.01335             0.00091                        0.025786      16.68           0.035761
  miRNA-19a-3p        −0.08618            −0.15284                       −0.019515     15.41           0.011985
  miRNA-19a-5p        0.01881             0.007                          0.030627      5.12            0.002358
  miRNA-20a-5p        −0.07285            −0.13287                       −0.012837     15.14           0.018026
  miRNA-21-5p         −0.08711            −0.16238                       −0.011839     15.01           0.02391
  miRNA-218-5p        0.01153             0.00195                        0.021105      10.47           0.01914
  miRNA-221-3p        −0.08579            −0.15833                       −0.013249     17.57           0.021091
  miRNA-29a-3p        −0.07983            −0.14971                       −0.00994      17.91           0.025736
  **miRNA-302a-3p**   **0.02139**         **0.01078**                    **0.032**     **6.59**        **0.00016**
  miRNA-182-5p        0.0118              0.00287                        0.020725      11.85           0.010358
  miRNA-30a-3p        0.01191             0.00057                        0.023248      15.27           0.039776
  miRNA-320a          −0.06294            −0.12578                       −0.000095     17.76           0.049664
  miRNA-196b-5p       0.01095             0.00053                        0.021373      13.32           0.039796
  miRNA-483-5p        0.01716             0.00639                        0.027934      11.56           0.002286
  miRNA-491-3p        0.01845             0.00683                        0.030061      6.19            0.002422
  miRNA-576-5p        0.0181              0.00557                        0.030625      17.2            0.005243
  miRNA-589-3p        0.01454             0.00373                        0.025357      10.29           0.009236
  miRNA-589-5p        0.01385             0.00123                        0.026474      4.77            0.032054
  miRNA-92a-3p        −0.09228            −0.16487                       −0.019692     13.8            0.013415
  miRNA-30a-5p        −0.083              −0.15325                       −0.012747     17.27           0.021215
  miRNA-26a-5p        −0.07741            −0.13605                       −0.018773     17.44           0.01036
  miRNA-24-3p         −0.05787            −0.11243                       −0.003314     17.55           0.037918
  miRNA-126-3p        −0.08408            −0.14623                       −0.021933     15.79           0.00868
  miRNA-451a          −0.08118            −0.14626                       −0.016095     9.84            0.015193
  let-7b-5p           −0.0718             −0.13272                       −0.0109       15.17           0.0215
  let-7c-5p           −0.06978            −0.12978                       −0.0098       16.75           0.02324

*Bolded miRNAs signify significant relationships after Bonferroni correction for p \< 0.0005. Cq, quantitation cycle; miRNA, microRNA*.

Thus, miRNAs downstream targets were analyzed using miRDB, an online database that captures miRNA and gene target interactions ([@B23], [@B24]). We do not have experimental data to guide selection of relevant downstream targets, and thus we included all predicted targets of miR-155-5p and−302a-3p in our analysis. As miRNA are known to act in concert, we used the combined targets of miR-155-5p and−302a-3p to perform further analysis ([@B26]). Ingenuity Pathway Analysis (IPA) was utilized to identify the molecular network and cellular toxicity pathways regulated by predicted targets. Canonical pathways were mapped to allow for visualization of the shared biological pathways through the common genes. The pathways identified and their associated genes are shown in [Supplementary Table 2](#SM1){ref-type="supplementary-material"} and the top 10 significant pathways are displayed in [Figure 2](#F2){ref-type="fig"}, including adipogenesis, cardiac hypertrophy, nerve growth factor (NGF), and IL-8 signaling.

![A network analysis of predicted targets of miR-155-5p and miR-302a-3p as performed by Ingenuity Pathway Analysis. Nodes represents signaling pathways, and lines are protein targets that are common between nodes. IL-8, Interleukin 8; NGF, Nerve Growth Factor; ERK5, Extracellular Related Kinase 5.](fcvm-06-00115-g0002){#F2}

Discussion {#s4}
==========

Due to its proximity to the autonomic ganglia, myocardium, and coronary arteries, epicardial adipocytes can influence neighboring cells via both paracrine and vasocrine signaling ([@B27]). EAT has been implicated in the pathogenies of AF. We and others demonstrated previously that EAT is associated with incident and severity of AF ([@B14], [@B28]). miRNAs regulate the molecular processes that trigger the structural and electrophysiological remodeling key to the development of AF ([@B6]--[@B9], [@B21]). They are associated with incident and recurrent AF, and their dynamic nature after catheter ablation suggests that they are related to the pathogenesis of AF ([@B5], [@B15], [@B21]). In this work, we explore the relationship between iLAEAT and plasma miRNA and hypothesize their potential role in creating a substrate for AF.

We found two circulating miRNAs, miRNA 155-5p and 302a-3p, significantly associated with iLAEAT. Our pathway analysis of the downstream targets of miRNAs 155-5p and 302a-3p implicated them in the regulation of adipogenesis, cardiac hypertrophy, IL-8, and NGF signaling. In our cohort, increased iLAEAT is associated with increased posterior wall thickness. It is possible that miRNAs 155-5p and 302a-3p regulate pathways to increase formation of adipocytes and myocyte hypertrophy, as evident by echocardiographic phenotypes. It is unclear to us why in our dataset there is a significant association between iLAEAT and PWT and not IVSTd or LV mass. Perhaps, iLAEAT is in close proximity to the posterior wall and thus is able to exert mechanical stress or paracrine effects to cause local hypertrophy. Alternatively, we may be under-powered to examine the differences in IVSTd or LV mass in different tertiles of iLAEAT.

EAT has been shown to secrete adipokines that influence electrical remodeling ([@B29]). Our analysis predicts that miRNA 155-5p and 302a-3p regulate NGF signaling. There is much evidence suggesting that autonomic remodeling plays an important role in the pathogenesis of AF ([@B30]--[@B32]). The ganglionated plexi (GP), consisting of autonomic ganglia, are located on the epicardial surface of the heart and are typically surrounded by EAT ([Figure 3](#F3){ref-type="fig"}) ([@B33]). Adipocytes have been shown to secrete NGF ([@B34]). NGF is up-regulated in the presence of AF and can induce the hyperactivity of GP ([@B32], [@B35]). In animal models, Yang et al. found that high plasma NGF levels create atrial substrate for AF and increase the incidence of inducible AF and its duration ([@B36]). Our analysis of miRNAs 155-5p and 302a-3p suggests a mechanism in which adipose tissue upregulates NGF to potentiate AF.

![Proposed functions of miR-155-5p and miR-302a-3p. Increase EAT with concurrent upregulation of miR-155-5p and miR-302a-3p cause changes in adipokine secretion such as IL-8 and NGF. These changes lead to autonomic dysregulation and increased inflammation, creating a substrate for atrial fibrillation.](fcvm-06-00115-g0003){#F3}

Several studies from the Sata laboratory have shown that EAT adipokine imbalance is a strongly linked of the development of atherosclerosis in men ([@B37]--[@B39]). Similarly, adipokines released from EAT may alter immune profiles the myocardium and surrounding tissue to increase inflammation and vulnerability to rhythm disturbances ([@B40]). Our results further support the hypothesis that EAT is an inflammatory mediator that is involved in adverse cardiac remodeling. EAT potentially contributes to inflammation and adverse structural remodeling via secretion of inflammatory adipokines such as IL-8 ([@B40], [@B41]). Circulating levels of IL-8 are associated to obesity-related factors such as BMI, waist circumference, C-reactive protein, interleukin (IL) 6, and tumor necrosis factor α (TNF-α) ([@B42]--[@B44]). IL-8, IL-6, IL-10, and TNF-α concentrations have been shown to be independently associated with AF ([@B45]). Patients with post-operative AF after coronary artery bypass graft surgery have higher serum IL-8 concentrations, indicating a role for inflammation in the development of AF post-surgery ([@B46]). miRNAs 155-5p and 302a-3p are implicated in the regulation of IL-8 and are associated with increased EAT, suggesting that secretion of IL-8 may be one of the ways in which EAT promotes inflammation to create a substrate for AF.

Strengths and Limitations {#s5}
=========================

We leveraged data from a prospectively enrolled contemporary cohort of participants with AF undergoing miRNA profiling, echo phenotyping as well as EAT quantification using cardiac CT. We analyzed plasma concentration levels of commonly expressed miRNAs in cardiomyocytes of a cohort of 91 patients undergoing CA and CT scans at UMMC.

Despite these study strengths, there are notable study limitations. Notably, we do not know the sources of the miRNAs, the mechanism by which they are found in the blood or if they are indeed involved in a signaling cascade. These biological questions are of great importance and will provide mechanistic insight. Unfortunately, they are beyond the scope of our study. Our modest sample size leaves for the possibility of falsely negative associations. This may explain why the negative association between iLAEAT and LAFI was not statistically significant. There is also a lack of diversity in patients sampled inhibits us from making generalizable claims. Furthermore, the associations made in this study between iLAEAT and miRNA expression are purely correlational. We have not tested a causal relationship between miRNAs 155-5p, 302a-3p and iLAEAT. Further experimentation at the bench is needed to elucidate the exact relationship between these miRNAs and EAT.

Conclusion {#s6}
==========

In this study, we assessed the relationship between relative EAT area and plasma miRNA expression in patients with AF. We observed a significant, positive association between relative EAT area and miRNAs 155-5p and 302a-3p. Future validation and mechanistic studies are needed to improve our understanding of the pathological role of EAT in AF development.
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